Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dongmei Chen
Institution:
China-Japan Friendship Hospital
Observed institutions:
The University of Texas MD Anderson Cancer Center,
China-Japan Friendship Hospital,
Taizhou Second People's Hospital,
Yangzhou University
ORCID:
0000-0002-3456-8492
Observed ORCID:
0000-0002-3456-8492
OpenAlex ID:
A5040309478
Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2023
·
Daoyan Wei
, Dongmei Chen
, et al.
·
Molecular Cancer Therapeutics
·
13
HIF-2α inhibitors in clear cell renal cell carcinoma: a clinical pharmacy perspective on lipid metabolism, therapeutic management, and resistance strategies
2025
·
Dongmei Chen
, Chunwang Hua
·
Frontiers in Medicine
·
7
PDF
Wuse-oil Compound 03 mitigates radiation-induced oral mucositis by modulating oral microbiota to mediate TLR4/NF-κB pathway and inhibit M1 macrophage polarization
2025
·
Liqun Jia
, Rong Huang
, et al.
·
Phytomedicine
·
5
Shengjiang Xiexin Decoction Mitigates Irinotecan-Triggered Delayed-Onset Diarrhea by Modulating Short-Chain Fatty Acids and the TLR4-MyD88-JNK/ NF-κB Pathway
2026
·
Chao Deng
, Yu Gao
, et al.
·
Current Pharmaceutical Design
·
1
Corrigendum to “Wuse-oil Compound 03 mitigates radiation-induced oral mucositis by modulating oral microbiota to mediate TLR4/NF-κB pathway and inhibit M1 macrophage polarization” [Phytomedicine volume 145 (2025) 157083]
2025
·
Liqun Jia
, Rong Huang
, et al.
·
Phytomedicine
Figure S1-S5 from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2025
·
Daoyan Wei
, Dongmei Chen
, et al.
Corrigendum to “Wuse-oil Compound 03 mitigates radiation-induced oral mucositis by modulating oral microbiota to mediate TLR4/NF-κB pathway and inhibit M1 macrophage polarization” [Phytomedicine volume 145 (2025) Start page–End page/157083]
2025
·
Liqun Jia
, Rong Huang
, et al.
·
Phytomedicine
Figure S1-S5 from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2024
·
Daoyan Wei
, Dongmei Chen
, et al.
Data from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2024
·
Daoyan Wei
, Dongmei Chen
, et al.
Figure S1-S5 from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2023
·
Daoyan Wei
, Dongmei Chen
, et al.
Figure S1-S5 from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2023
·
Daoyan Wei
, Dongmei Chen
, et al.
Data from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2023
·
Daoyan Wei
, Dongmei Chen
, et al.
Data from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
2023
·
Daoyan Wei
, Dongmei Chen
, et al.
Show more works
View as search
Works count:
13
Citation count:
26
H-index:
3
I10-index:
1
Year
Topic
Type